Korea Centers for Disease Control and Prevention (KCDC) chief Jeong Eun-kyung is giving a special briefing on the corona 19 vaccination at the briefing room of the Centers for Disease Control and Prevention in Osong-eup, Cheongju-si, Chungcheongbuk-do. On the left is Choi Won-seok, a professor of infectious medicine at Korea University Ansan Hospital. News 1
Korea Centers for Disease Control and Prevention (KCDC) Commissioner Jeong Eun-kyung said that he would also consider introducing Russia’s’Sputnik V’in relation to the novel coronavirus infection (Corona 19) vaccine.
In the’Citizen Participation Special Briefing’ of the Korean Disease Service Vaccination Promotion Team on the 8th, Commissioner Chung said, “There are uncertainties regarding the Sputnik V vaccine in Russia, such as the issue of (virus) mutations or (other vaccines) supply. We will continue to review the necessity and content of securing.”
Sputnik V, developed by the National Center for Infectious Diseases and Microbiology in Gamaleya, Russia, showed 91.6% efficacy as a result of a phase 3 interim analysis.
Commissioner Chung said that the controversial AstraZeneca vaccine due to the lack of clinical trial data for the elderly was “is looking at additional clinical trial results,” and said, “The Central Pharmacist Review Committee’s results are also to allow vaccinations for those over 18 years old. Therefore, I think I will have to see the contents of the license and the results of the clinical trials.”
It also explained that it is planning to secure NovaVax vaccine. Commissioner Chung said, “If a contract between NovaVax of the United States and SK Bioscience is signed, we are also currently considering signing a contract with SK Bioscience.”
Reporter Na Unchae [email protected]